Cost-effectiveness analysis of capivasertib plus fulvestrant in the <i>PIK3CA/AKT1/PTEN</i

A 2026 partitioned survival model evaluates the cost-effectiveness of capivasertib plus fulvestrant versus fulvestrant monotherapy for HR+/HER2− advanced breast cancer with specific genetic alterations. The analysis, authored by Xi Liang and published on figshare, uses a 5-year time horizon with data from the CAPItello-291 trial and U.S. payer costs. It calculates incremental cost-effectiveness ratios (ICERs) based on quality-adjusted life-years (QALYs) and life years gained.

Use Cases

• Conducting pharmacoeconomic modeling based on partitioned survival model methodology described.
• Analyzing the impact of drug price on cost-effectiveness based on the reported threshold analysis for capivasertib.
• Comparing incremental cost-effectiveness ratios (ICERs) against willingness-to-pay thresholds based on the reported QALY and evLYG outcomes.
• Performing sensitivity and scenario analyses for oncology treatments based on the described 5-year and 10-year horizon models.

Strengths

• Model is based on clinical trial data from CAPItello-291 (NCT04305496).
• Costs and outcomes are presented with specific figures, including a $636,455/QALY ICER and a $28,332/4-week drug cost.
• Analysis includes sensitivity, scenario, and threshold analyses to test model robustness.

Limitations

• Extrapolation of survival data reflects limited long-term trial data, increasing parameter uncertainty.
• Efficacy based on clinical trials may differ from real-world effectiveness.
• Row count and column-level documentation are absent; data structure must be inferred from the description.

Provenance

Source

figshare, author Xi Liang.

Collection Method

Partitioned survival model developed using data from the CAPItello-291 trial, published literature, and Centers for Medicare and Medicaid Services costs.

Time Range

Model uses a 5-year time horizon with costs in 2025 U.S. dollars.

Freshness

Last updated 2026-04-20 23:05:40.

Geography

United States (U.S. payer perspective).